Background: Allogeneic stem-cell transplantation (SCT) is a well-established immunotherapeutic strategy for multiple myeloma (MM) with a potent and often sustained graft-vs.-myeloma effect. This multicenter investigation aimed to analyze the complications and survival of haploidentical SCT in patients with MM, and compare the main outcomes with matched-related donors (MRDs). Methods: Haploidentical and MRD SCT was identified from a cohort of 97 patients with MM who received a myeloablative transplantation in 13 hospitals from May 2001 to December 2017. A matched-pair analysis was designed. For each haplo recipient, the recipients were randomly selected from the MRD group and were matched according to the following criteria: year of the hematopoietic SCT (±2 years), disease status at transplantation, and the length of follow-up. Results: Seventy cases received MRD and 27 received haploidentical transplantation. The two groups showed no significant differences regarding age, gender, cytogenetic risk, and diagnostic stage. The cumulative incidences of non-relapse mortality (NRM) at 1 and 3 years based on donor type were 20.5% (95% confidence interval [CI], 10.90-30.10%) and 24.2% (95% CI, 13.81-34.59%) for the MRD group and 16.80% (95% CI, 1.71-31.89%) and 28.70% (95% CI, 8.71-48.69%) for the haplo group, respectively. Cumulative incidence of NRM did not differ significantly between the two groups (x 2 = 0.031, P = 0.861). The cumulative incidences of progression-free survival (PFS) and 1 year and 3 years by type of donors were 59.8% (95% CI, 48.24-71.36%) and 45.4% (95% CI, 33.44-57.36%), and 65.6% (95% CI, 47.18-84.02%) and 26.8% (95% CI, 7.59-46. 01%) for MRD and haploidentical donor, respectively. Cumulative incidence of PFS did not differ significantly between the two groups (x 2 = 0.182, P = 0.670). In multivariate analyses, no statistically significant differences were observed between haploidentical and MRD for relapse, NRM, PFS, and overall survival. There were no statistically differences on main outcomes after haploidentical and MRD. Conclusion: Haploidentical SCT could be performed safely and feasibly for patients with MM in need.
Introduction
Allogeneic stem-cell transplantation (allo-SCT) is a wellestablished immunotherapeutic strategy for multiple myeloma (MM) with a potent and often sustained graftvs.-myeloma effect. [1, 2] Therefore, allo-SCT continues to be offered to a significant portion of patients with relapsed/ refractory or ultra-high risk MM. During early stage of this treatment, treatment-related mortality (TRM) following allo-SCT for MM has reportedly ranged from 40% to 60%. [3] [4] [5] [6] Since then, the TRM after myeloablative and reduced intensity conditioned allo-SCT has decreased with time (48% TRM between 1995 and 2000 vs. 29% TRM between 2001 and 2005) and further improvements are expected owing to improvements in supportive care and new preparative regimens. [7] Transplantation from a haploidentical family donor has become an established procedure to treat patients with malignant hematologic diseases including relapsed or refractory acute leukemia and lymphoma and serves as a treatment alternative for high-risk hematologic malignant disorders. [8] [9] [10] [11] Modified or intensified conditioning regimens and improved supportive care has yielded improved outcomes after haploidentical SCT (haplo-SCT) with decreased treatment-related toxicity and infections, compared to conventional SCT. [12] [13] [14] Haplo-SCT has received increasing attention as an alternative to human leukocyte antigen (HLA)-matched SCT in emergent cases. However, limited information is available regarding the use of other alternative donors, such as haploidentical grafts in patients with MM. [15, 16] Previously, we reported the safety and efficacy of using grafts from matched sibling donors to treat MM. [17, 18] Accordingly, we performed a registry-based study to evaluate the outcomes of transplantation among patients receiving grafts from various donor types including matched siblings and haploidentical-related donors to analyze the role of donor type in MM.
Methods

Ethical approval
The study was conducted in accordance with the tenets of the Declaration of Helsinki. All patients provided informed consent for research. As a retrospective study and data analysis was performed anonymously, this study was exempt from the ethical approval.
Study design, inclusion criteria, and data collection
This retrospective registry-based study involved consecutively data on Chinese patients aged over 18 years and diagnosed with MM or plasma cell leukemia (PCL), receiving allogeneic SCT from May 2001 to December 2017. Exclusion criteria were as follows: history of allo-SCT, unrelated donors, non-myeloablative conditioning regimens, received cord blood as a source of stem cells, and unknown donor type. Patients with matched-related donors (MRDs) were assigned to the MRD group; patients with haploidentical-related donors, haplo group. A matched-pair analysis was designed. For each haplo recipient, the recipients were randomly selected from the MRD group and were matched according to the following criteria: year of the hematopoietic SCT (±2 years), disease status at transplantation and the length of follow-up.
Endpoints and definitions
The primary endpoint was progression-free survival (PFS) defined as time from allogeneic SCT to progression, relapse, or death from any cause, whichever occurred first. Secondary endpoints were neutrophil and platelet recovery, acute, and chronic graft-vs.-host disease (GVHD), non-relapse mortality (NRM), relapse incidence, and overall survival (OS). OS was defined as time from transplant to death from any cause.
Neutrophil engraftment was defined as the first of 3 consecutive days with an absolute neutrophil count ≥0.5 Â 10 9 /L, without evidence of autologous reconstitution. Platelet engraftment was defined as the first date at which an unsupported platelet count of ≥20 Â 10 9 /L for 7 consecutive days was achieved. GVHD was evaluated on the basis of standard criteria.
The myeloablative regimen was defined as a regimen containing total-body irradiation (TBI) with a dose of >6 Gy, >8 mg/kg oral, or >6.4 mg/kg intravenous busulfan (BU) or multiple chemotherapy combinations involving high-dose carmustine, etoposide, cytarabine, and melphalan. [19, 20] Response to treatment was defined in accordance with standard criteria defined previously. [21] Complete response (CR) was defined by negative serum and urine immunofixation and 5% or less plasma cells with normal morphologic features in a bone marrow aspirate. A very good partial response (VGPR) was defined as a 90% reduction in serum paraprotein levels; partial response (PR), a 50% reduction in serum paraprotein levels or a 90% reduction in Bence-Jones protein levels (including patients with Bence-Jones protein alone) or both; stable disease (SD), no change in serum paraprotein levels; progressive disease (PD), a 25% increase in serum paraprotein levels; relapse, resurgence of serum paraprotein, recurrence of bone marrow infiltration, or both in patients displaying a CR and a 50% increase beyond the plateau levels of serum paraprotein in two samples obtained 4 weeks apart from a responder. High-risk cytogenetic abnormalities included del17p, t(4;14), or t (14;16), analyzed via fluorescence in situ hybridization, or conventional metaphase cytogenetics.
Statistical analysis
Categorical variables and quantitative data from the haploidentical and MRD groups were compared using the Chi-squared test and the non-parametric test, respectively. PFS and OS were measured in days and calculated from the date of allo-SCT until the respective events. NRM was defined as death from any cause, which occurred without previous progression or relapse after transplantation. The univariate probabilities of acute GVHD (aGVHD), chronic GVHD (cGVHD), NRM, relapse, OS, and PFS were calculated using cumulative incidence curves to account for competing risks. The effect of donor type on NRM, relapse, OS, and PFS was assessed using the Cox regression analysis. Any covariates with a P value of <0.1 on univariate analysis were included in the multivariate analysis. All P values were based on two-sided hypothesis tests, and the a-value was set at 0.05. The endpoint of the last follow-up for all surviving patients was October 14, 2018. SPSS 19.0 (IBM, Chicago, IL, USA) was used for statistical analysis.
Results
Patient and transplant characteristics are summarized in Table 1 . From 2001 to 2017, 97 patients from 13 centers, who fulfilled the eligibility criteria, were included. The median age at transplantation was 45 (range, 25-63) years. The median time from diagnosis to transplantation was 265 (range, 78-2619) days. Diagnosis was MM for 93 (95.9%) patients and PCL for four (4.1%) patients. Only 12 (12.4%) patients ) and ten (37.0%) patients in the MRD and haplo groups had a PR status less than that of SD, PD, and NR, respectively (P = 0.009). The most common conditioning regimen was BU and cyclophosphamide (CTX) administered to 62 (63.9%) patients. The combination of cyclosporine A (CsA), mycophenolate mofetil, and a short course of MTX was the most frequent (n = 90, 92.8%) GVHD prophylaxis. Peripheral blood stem cells were the most frequently used as stem cell sources for 56 of 97 (57.7%) transplants, whereas combined bone marrow and peripheral blood stem cells were used in 37 transplants (38.1%).
Hematologic engraftment
The 21-day cumulative incidences of neutrophil recovery for the MRD and haplo groups were 94.3% (95% confidence interval [CI], 88.8-99.8%) and 92.3% (95% CI, 82.1-100%), respectively (x 2 = 3.791, P = 0.052). The 60-day cumulative incidences of platelet recovery for the MRD and haplo groups were 97.0% (95% CI, 92.9-100%) and 92.3% (95% CI, 82.1-100%), respectively. Platelet engraftment was significantly lower in the haplo group than in the MRD group (x 2 = 3.729, P = 0.030).
Acute and chronic GVHD
Cumulative incidences of grades 2 to 4 acute GVHD at day 100 were 29.2% (95% CI, 18.0-40.4%), and 23.0% (95% CI, 6.9-39.1%) for MRD and haplo groups, while the corresponding probabilities of grade 3 or 4 acute GVHD on day 100 were 7.1% (95% CI, 1.0-13.2%) and 3.7% (95% CI, 0-10.8%), respectively; the risk of acute GVHD being similar between the two groups (x 2 = 0.142, P > 0.05).
For the entire patient cohort, the 3-year cumulative incidence of chronic GVHD was 28.4% (95% CI, 14.7-42.1%) and 77.9% (95% CI, 52.4-100%) for MRD and haplo groups, respectively. The risk of chronic GVHD was significantly higher in the haplo group than in the MRD group (x 2 = 3.897, P = 0.045). Figure 1A ]. Cumulative incidence of NRM did not differ significantly between the two groups (x 2 = 0.031, P = 0.861). A transplantation later than 2010 was an independent significant factor that decreased NRM incidence upon multivariate analysis (hazard ratio [HR], 0.296; 95% CI, 0.132-0.663; P = 0.003). Figure 1B ]. Cumulative incidence of relapse did not differ significantly between the two groups (x 2 = 0.865, Figure 1C ]. Cumulative incidence of PFS did not differ significantly between the two groups (x 2 = 0.182, P = 0.670). Furthermore, a status lower than PR was an independent risk factor for relapse upon multivariate analysis (HR, 1.939; 95% CI, 1.108-3.393; P = 0.02).
Other major outcomes
The cumulative incidences of OS at years 1 and 3 were 72.8% (95% CI, 62.41-83.19%) and 60.1% (95% CI, 48.34-71.86%) for the MRD group and 68.8% (95% CI, 50.77-86.83%) and 37.5% (95% CI, 15.94-59.06%) for the haplo group, respectively [ Figure 1D ]. The probabilities of OS did not differ significantly between the two groups (x 2 = 1.484, P = 0.223). Furthermore, Tables 3  and 4 show the results of univariate analysis of risk factors regarding their association with clinical outcomes. In summary, the present results indicated that patients with higher tumor burden at transplant had higher relapse rates. Moreover, donor type was not associated with NRM, relapse, DFS, or OS (P > 0.05, Tables 3 and 4 ).
Discussion
This retrospective study evaluated the feasibility of allogeneic SCT for MM, including grafts from MRD and haploidentical donors. One patient in MRD groups died of graft rejection, and the others achieved successful engraftment. The cumulative incidence of acute GVHD was similar between the MRD and haplo groups. A European Society for Blood and Marrow Transplantation analysis of 4726 patients who underwent allo-SCT reported an NRM of 19% to 30% after 2004. [22] Concurrently, the present study reported that the cumulative incidence of NRM at 1 and 3 years was 19.5% and Notably, the cumulative incidence of NRM at 1 and 3 years were comparable between the MRD and haplo groups. Twenty-eight-day neutrophil recovery was not significantly different between the haplo and MRD groups. Furthermore, the cumulative incidence of either grade acute GVHD was comparable between the two groups; however, the haplo group displayed a greater frequency of chronic GVHD than the MRD group. Compared with the MRD population, the possibility of those with an increased incidence of chronic GVHD having a relatively beneficial graft-vs.-myeloma effect warrants verification via further case studies.
Better clinical outcomes are probably associated myeloma chemosensitivity during transplantation. Patients with a status lower than PR did not benefit from allo-SCT and had a higher risk of relapse. Considering high-risk features, cytogenetic aberrations are notably associated with an unfavorable prognosis in patients with MM receiving standard therapies. In the current study, high-risk cytogenetic aberrations were not a poor prognostic factor for major outcomes. Concurrent with the observation by Schilling et al and Roos-Weil et al, allo-SCT might overcome the adverse prognosis of high-risk cytogenetic aberrations. [23, 24] Overall, the risk of relapse was still high even after allo-SCT. In our series, the cumulative incidence of relapse at 3 years was as high as 44.4% and 57.6% the for MRD and haplo groups, respectively; however, these rates are comparable to previous reports regarding allo-SCT for MM. Notably, approximately 85% were of a CR/VGPR/ PR status before transplantation in the MRD group; however, those in the haplo group were less chemosensitive (63%). Although pre-transplantation remission rates are important, molecular evaluation of minimal-residual disease significantly influences the detection of disease recurrence, [25, 26] where immediate therapeutic intervention could extend the duration of remission and survival in a low-risk situation. Therefore, strategies to prevent relapse after allo-SCT may include a series of minimal residual disease monitoring and maintenance with immunomodulatory drugs, proteasome inhibitors, or targeted cell immunotherapy. [27] [28] [29] Naturally, the present study has some limitations inherent to a retrospective analysis. First, conditioning regimens differed and were not standardized. A few regimens included TBI, no significant effect was observed in the outcomes between the TBI and non-TBI groups. Second, information, cytogenetic stratification data, DS stage, and the International Staging System stage were also not available for each patient. Third, maintenance therapy and subsequent salvage regimens after transplantation were unavailable and seemed to vary owing to the long treatment duration from 2001 to 2017. Fourth, this study had a small cohort, thereby precluding definitive conclusions regarding a comparison of clinical outcomes. The limited number of patients in the haplo group was also a strong limitation to analyze outcomes. Hence, comparisons should be explained with caution. And it would be helpful to highlight patients with longer follow-up on survival.
In conclusion, the present results showed no significant differences in the outcomes between patients with MM receiving grafts from MRD and haploidentical donors. Although allo-SCT provided long-term survival for a fraction of patients, post-transplantation maintenance therapy remains a key issue, even in chemosensitive patients treated first via allo-SCT. In addition, strategies to enhance a graft-vs.-myeloma effect after transplantation should be investigated to decrease disease progression.
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